Table 1 Characteristics of the studies included in the meta-analysis
Author, yr | Study yr | Mean (SD) age in yr | Gravida | Study design | Country | Index test | Manufacture/brand name | Ref test | tp | fp | fn | tn | Sample size | Parasite density | Remarks |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kapisi 2017 [30] | 2014 | 21(4.2)$ | Pri (46.6%)$ | Nested cohort | Uganda | LAMP | Eiken Loopampâ„¢ | Microscopy | 24 | 0 | 1 | 255 | 280 | NA | HIV -ves |
Natureeba 2017 [31] | 2014 | 30 | Multi (82%) | RCT | Uganda | LAMP | Eiken, Japan | Microscopy | 0 | 0 | 2 | 96 | 98 | NA | HIV + ves |
Tadesse 2020 [32] | 2018–2019 | 26.2 (4.6) | Multi (75.8%) | L | Southwest Ethiopia | LAMP | Meridien Bioscience, Cincinnati, OH | Microscopy | 5 | 4 | 0 | 426 | 435 | mean 882.7 p/µL |  |
2018–2019 | 26 | Multi (56.0%) | L | Southwest Ethiopia | LAMP | Meridien Bioscience, Cincinnati, OH | RDT (HRP2/pLDH combo) | 6 | 3 | 0 | 426 | 435 |  | ||
Tegegne 2017 [33] | 2016 | 27 | Multi (74.7%) | CS | Northwest Ethiopia | LAMP (Pan/Pf) | Eiken Chemicals, Tokyo | nPCR | 10 | 5 | 0 | 72 | 87 | 3380 p/µL |  |
Tran 2020 [34] | 2014 | 21(md) | Pri (38.2%) | Secondary data from an RCT | Uganda | LAMP | Eiken Chemical | Microscopy | 23 | 0 | 78 | 127 | 228 | NA | Â |
Vasquez 2018 [35] | 2016–2017 | 24 (IQR, 20–28)1 | Pri (49.3%) | Prospective | Colombia | Pan-LAMP, Pf-LAMP | Eiken Chemicals, Tokyo | nPCR | 39 | 0 | 0 | 492 | 531 | 2480 p/µL(md) |  |
Vasquez 2020 [36] | 2017–2018 | 24 (IQR, 20–29)1 | Pri (30.5%) | CS | Colombia | Pan-LAMP, Pf-LAMP | Loopamp™ MALA RIA Kit, Eiken Chemical Company | qRT-PCR | 35 | 1 | 4 | 818 | 858 | geometric mean of 13.2 p/µL |  |
Samuels 2022 [37] | 2018 | 23 (IQR 20–28) | Pri (25.5%) Section (25.9%) multi (48.6%) | Prospective | Kenya | LAMP | Meridian Bioscience, Illumigene Malaria | PET PCR | 118 | 55 | 54 | 310 | 482 | < 200 p/µL$$ |  |